Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01122199
Other study ID # 1002-16; IUCRO-0287
Secondary ID
Status Completed
Phase Phase 1
First received May 7, 2010
Last updated May 9, 2017
Start date May 14, 2010
Est. completion date January 19, 2015

Study information

Verified date May 2017
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of the combination of two drugs called RAD001 and AMG479. This study will see what effects (good and bad) RAD001 and AMG479 have on cancer. This study will also find the highest doses of RAD001 and AMG479 that can be given without causing severe side effects.


Description:

PRIMARY OBJECTIVES:

I. To determine the maximum tolerated (MTD) and recommended Phase II doses for AMG479 (ganitumab) and RAD001 (everolimus) in patients with refractory solid tumors.

II. To determine the safety and toxicity of AMG479 and RAD001.

SECONDARY OBJECTIVES:

I. To determine preliminary antitumor efficacy of AMG479 and RAD001 in solid tumors: response and stable disease rates, duration of response and of stable disease, time to progression (TTP) and overall survival (OS).

II. For all patients, to analyze tumor and blood samples for pharmacodynamic biomarkers related to IGF-1R and mTOR signaling: pAkt, pS6, p-4EBP1, PTEN, IGF-1, IGF-2, pIGF-1R and IGFBP3 and correlate with response and stable disease.

III. For all patients, to analyze the pharmacokinetic profile (PK) for RAD001 and AMG479, and correlate with response/stable disease and pharmacodynamic markers.

IV. To evaluate the effects of RAD001 on AMG 479 pharmacokinetics.

OUTLINE: This is a dose-escalation study.

Patients receive everolimus orally (PO) once daily (QD) on days 1-28 (days 1-7 and 16-28 of course 1 only) and ganitumab intravenously (IV) over 60 minutes on days 1 and 15 (day 15 of course 1 only). Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at day 30, every 3 months for 2 years from registration for study treatment, every 6 months for years 3-5, and then annually thereafter.


Recruitment information / eligibility

Status Completed
Enrollment 27
Est. completion date January 19, 2015
Est. primary completion date January 19, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histological or cytological proof of metastatic solid tumor refractory to standard therapies, or for which no standard therapies are available.

- Patients in the expansion cohort must have a measurable site of disease according to RECIST (v 1.0)

- Laboratory values must be obtained within protocol limits and obtained within 14 days prior to registration

- Patients must have disease which is not amenable to potentially curative surgical resection of metastatic disease (curative metastasectomy).

- Must be willing to provide metastatic tissue biopsy samples (may be paraffin embedded) at baseline

- Must be willing to undergo a metastatic tissue biopsy after 2 cycles of therapy to perform pharmacodynamic research biomarkers testing.

- Subjects must be willing and able to abstain from using strong or moderate CYP3A4 inhibitors or inducers during the study period.

Exclusion Criteria:

- No symptomatic brain metastasis

- No prior treatment with an mTOR inhibitor or with an IGF-1R inhibitor

- No known history of diabetes mellitus

- No thrombosis or vascular ischemic events within the last twelve months

- No chronic treatment with systemic steroids or another immunosuppressive agent

- No active bleeding or a pathological condition that is associated with a high risk of bleeding

- No known history of HIV seropositivity

- No known history of Hepatitis B or Hepatitis C seropositivity

- No known hypersensitivity to AMG 479, RAD001 (everolimus), other rapamycins (sirolimus, temsirolimus), or to its excipients

- No planned immunization with attenuated live viruses during the study period

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RAD001 + AMG479
Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.

Locations

Country Name City State
United States Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana

Sponsors (3)

Lead Sponsor Collaborator
Shadia Jalal Amgen, Novartis

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To determine the maximum tolerated (MTD) and recommended Phase II doses for AMG479 and RAD001 in patients with refractory solid tumors 1 year
Primary To evaluate the grade and severity of adverse events as a measure of safety and toxicity 2 years
Secondary To determine preliminary antitumor efficacy of AMG479 and RAD001 in solid tumors response and stable disease rates, duration of response and of stable disease, time to progression (TTP) and overall survival (OS) 5-10 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03911388 - HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors Phase 1
Completed NCT02953756 - Cognitive Outcome After Gamma Knife Radiosurgery in Patients With Brain Metastases (CAR-Study A)
Terminated NCT02565433 - Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302) N/A
Completed NCT00184353 - Clinical MR Spectroscopy of Brain Metastases at 1,5T and 3T. N/A
Recruiting NCT02789371 - Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions N/A
Terminated NCT01336985 - Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads Phase 1
Recruiting NCT05419518 - Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas Phase 2
Completed NCT02808416 - Personalized Cellular Vaccine for Brain Metastases (PERCELLVAC3) Phase 1
Completed NCT00668382 - Evaluate The Toxicity And Feasibility Of Intra-Tumoral Injection Phase 1
Completed NCT00152906 - Stereotactic Radiotherapy (SRT) Liver (COLD 1) Phase 1/Phase 2
Completed NCT01267084 - A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies Phase 1/Phase 2
Recruiting NCT02327065 - Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion N/A
Completed NCT02382653 - Oral Piroxicam Versus Buccal Fentanyl in Breakthrough Pain N/A
Completed NCT01273480 - A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies Phase 1
Completed NCT01273493 - A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction Phase 1
Completed NCT00556049 - Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT02246634 - Screening for Synchronous Metastases in Colorectal Cancer With DW-MRI (SERENADE) N/A
Terminated NCT01970644 - Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases N/A

External Links